Citius Pharmaceuticals (NASDAQ: CTXR) — Perfil da empresa, notícias e dados financeiros
Citius Pharmaceuticals develops anti-infectives and cancer care products, focusing on addressing critical unmet medical needs.

Citius Pharmaceuticals
Citius Pharmaceuticals (NASDAQ:CTXR) is a dynamic company focused on developing and commercializing critical care products with a special emphasis on anti-infectives, cancer care, and unique prescription products that use proprietary, patented, or exclusive formulations and delivery systems. With a passion for improving patient outcomes, their projects range from early to late-stage development, ensuring a pipeline filled with potential market-changing solutions. Their objectives are centered around addressing the unmet needs in high-value areas of medical care, striving to bring new, effective treatments to market as swiftly and safely as possible. By dedicating resources to both research and the advancement of novel therapeutics, Citius aims to revolutionize treatment protocols and improve the quality of life for patients around the globe.
Resumo
Operações
Produtos e/ou serviços de Citius Pharmaceuticals
- Mino-Lok: An antibiotic lock solution aimed at treating catheter-related bloodstream infections.
- Halo-Lido: A formulation designed for relieving discomfort and symptoms associated with hemorrhoids.
- Mino-Wrap: A liquefying gel-based wrap for reducing post-operative infections in breast implants.
- CNSA-001: An oral formulation of sepiapterin for treating phenylketonuria (PKU), aiming to enhance the quality of life for patients.
equipe executiva do Citius Pharmaceuticals
- Leonard L. MazurCo-Founder, CEO, Chairman & Secretary
- Myron Z. HolubiakCo-Founder & Executive Vice Chairman
- Myron S. CzuczmanExecutive VP & Chief Medical Officer
- Jaime BartushakChief Business Officer & CFO
- Gary F. TalaricoExecutive Vice President of Operations
- Ilanit AllenVice President of Investor Relations & Corporate Communications
- Alan LaderSenior VP and Head of Clinical Operations & Quality Assurance
- Dhananjay G. WadekarSenior Vice President of Business Strategy
- Kelly CreightonExecutive Vice President of Chemistry, Manufacturing & Controls
- Nikolas BurlewExecutive Vice President of Quality Assurance
Principais indicadores financeiros
Resultados divulgados pela Citius Pharmaceuticals, em USD.
- Cap. de mercado
- 14,9 mi
- Receita (TTM)
- 7,1 mi
- P/L
- —
- LPA (diluído, TTM)
- -1.8
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -38,5 mi | -37,4 mi | |
| 0 | -42 mi | -39,1 mi | |
| 0 | -36,7 mi | -32,5 mi | |
| 0 | -33,3 mi | -33,6 mi |